Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- 5 June 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 17 (7), 917-927
- https://doi.org/10.1016/s1470-2045(16)30107-3
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinomaAnnals of Oncology, 2013
- Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management StrategiesJNCI Journal of the National Cancer Institute, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- Phase 3 trial of everolimus for metastatic renal cell carcinomaCancer, 2010
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and SurvivalClinical Cancer Research, 2009
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008